REG - Eco Animal Health Gp - AGM Trading Update and Notice of Interim Results

ECO Animal HealthAnnouncement

25/09/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250925:nRSY7127Aa&default-theme=true

RNS Number : 7127A  Eco Animal Health Group PLC  25 September 2025

25 September 2025

ECO Animal Health Group plc

("ECO" or the "Company")

 

AGM Trading Update and Notice of Interim Results

Strong trading year to date, strongly ahead of prior year

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health
company with a portfolio of marketed veterinary products and a maturing
proprietary R&D pipeline, announces the following trading update for the
six months ending 30 September 2025, ahead of its Annual General Meeting being
held at 9.00 a.m. this morning.

Trading Update

Trading in the first half of this financial year has been significantly
stronger compared to the same period last year despite currency headwinds and
tariff challenges, with an expected increase in revenue of over 15% (H1 2025:
£33.2 million). This revenue strength has been particularly evident in the
China/Japan segment (greater than 40% growth) and North America (greater than
25% growth). Continuing strength in Brazil has been offset by some weakness
elsewhere in Latin America.  The South East Asia region has recovered much of
the ground lost in the prior year.

The Company also expects to report improved gross margins for the period,
which will translate into a material increase in adjusted EBITDA compared with
the first half of the prior year (H1 2025: £0.4 million).

It is expected that this strength in the first half will result in a more
balanced first and second half weighting than has been experienced in recent
years and provides the Board with increased confidence of a successful full
year outcome in line with current market expectations.(1)

Interim Results

The Company's interim results for the six-month period ending 30 September
2025 will be announced in late November 2025.

 

(1) The consensus market expectations for revenue and adjusted EBITDA for the
year ending 31 March 2026 are £84.2m and £7.9m respectively.

-Ends-

 

Contacts

                                                                020 8447 8899

 ECO Animal Health Group plc

 David Hallas (Chief Executive Officer)

 Christopher Wilks (Chief Financial Officer)

 ICR Healthcare (Financial PR)                                  020 3709 5700

 Mary-Jane Elliott

 Jessica Hodgson

 Singer Capital Markets (Nominated Adviser & Joint Broker)      020 7496 3000

 Philip Davies

 Sam Butcher

 Panmure Liberum (Joint Broker)                                 020 3100 2000

 Emma Earl

 Will Goode

 Mark Rogers

 Rupert Dearden

 Equity Development                                             020 7065 2692

 Hannah Crowe

 Matt Evans

 

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing
branded veterinary pharmaceuticals globally, with expertise in antibiotics and
vaccines for pigs and poultry. We have a maturing proprietary R&D
pipeline.

 

Headquartered in the UK, with global offices including R&D and
manufacturing, we have marketing authorisations in over 70 countries and
employ over 200 people worldwide.

 

Our lead product, Aivlosin(®) is a proprietary, patented medication which is
effective against both respiratory and intestinal diseases in pigs and
poultry.

 

Click here for more information: https://ecoanimalhealth.com
(https://ecoanimalhealth.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOREAXNLAFLSEFA